The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.
 
Ursula A. Matulonis
Consulting or Advisory Role - 2X Oncology; Clovis Oncology; Fujifilm; Geneos; Lilly; Merck; Myriad Genetics
Research Funding - Merck; Novartis
 
Ronnie Shapira-Frommer
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - MSD
 
Alessandro Santin
No Relationships to Disclose
 
Alla Sergeevua Lisyanskaya
No Relationships to Disclose
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Tesaro (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Francesco Raspagliesi
Honoraria - Roche
Speakers' Bureau - Roche
 
Gabe S. Sonke
Consulting or Advisory Role - Novartis (Inst)
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
 
Michael Birrer
No Relationships to Disclose
 
Diane M. Provencher
Consulting or Advisory Role - AstraZeneca
 
Jalid Sehouli
Honoraria - AstraZeneca; PharmaRx; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Novocure; Roche
Research Funding - Amgen; Lilly; Novartis
 
Nicoletta Colombo
Employment - Ignyta (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech
 
Antonio González-Martín
Consulting or Advisory Role - AstraZeneca; PharmaMar; Roche; Tesaro
Speakers' Bureau - AstraZeneca; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro
 
Ana Oaknin
Consulting or Advisory Role - Clovis Oncology; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
P. B. Ottevanger
Research Funding - Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - MSD; Roche
 
Vilius Rudaitis
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - MSD; Olympus; Roche
 
Kia Katchar
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Zhen Wang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jane Ruman
Employment - Merck
 
Jonathan A. Ledermann
Honoraria - AstraZeneca/MedImmune; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Pfizer; Roche
Speakers' Bureau - Clovis Oncology; Pfizer
Research Funding - AstraZeneca